Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients

Alberico L. Catapano, Michael H. Davidson, Christie M. Ballantyne, William E. Brady, Russell A. Gazzara, Joanne E. Tomassini, Andrew M. Tershakovec

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses. Research design and methods: Double-blind, multicenter, 6-week, parallel-group study in hypercholesterolemic patients (n = 2959). Patients were randomized based on stratification by low-density lipoprotein cholesterol (LDL-C) levels to ezetimibe/simvastatin or rosuvastatin, respectively, at the usual starting (10/20 or 10 mg/day), the next highest (10/40 or 20 mg/day), and maximum doses (10/80 or 40 mg/day). Results: At all doses and across doses, ezetimibe/simvastatin reduced LDL-C levels significantly more (52-61%) than rosuvastatin (46-57%; p ≤, 0.001). Significantly greater percentages of all patients (p <0.001) and high risk patients (p ≤, 0.005) attained LDL-C levels <70 mg/dL (1.8 mmol/L) following ezetimibe/simvastatin treatment compared with rosuvastatin at the prespecified doses and across doses. Ezetimibe/simvastatin also produced significantly greater reductions in total cholesterol (p <0.001), non-high-density lipoprotein cholesterol (p <0.001), lipid ratios (p

Original languageEnglish
Pages (from-to)2041-2053
Number of pages13
JournalCurrent Medical Research and Opinion
Volume22
Issue number10
DOIs
Publication statusPublished - Oct 2006

Keywords

  • Apolipoprotein B
  • CRP
  • Ezetimibe/simvastatin
  • HDL-C
  • Hypercholesterolemia
  • Lipids
  • Rosuvastatin
  • Statins

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients'. Together they form a unique fingerprint.

Cite this